Sun Pharma reports Q4 net loss of ₹2,277 crore
thehindu.com
news
2022-05-30 15:47:54

Sun Pharmaceutical Industries Ltd. reported net loss of ₹2,277.2 crore for the fourth quarter ended March 31 compared to net profit of ₹894 crore in the year-earlier period. This was on account of an exceptional item of ₹3,935.7 crore towards settlement payments and provisions related Taro Pharmaceuticals & Ranbaxy. Consolidated sales from operations during the quarter at ₹9,386.1 crore, grew 11%. India formulation sales at ₹3,095.6 crore, rose 16%. U.S. formulation sales at $389 million, grew 5% and Emerging Markets formulation sales at $206 million, grew 7%.
